Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancers.

J Hematol Oncol · 2021 · PMC7927217 · PMID 33653367

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

2 a, all patient cohorts showed a trend that the patients harboring KMT2 family mutation had a better durable clinical benefit (DCB) and most of them were statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.